Sep 02, 2026
Partners
TScan is a clinical-stage biotechnology company advancing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with hematologic malignancies and solid tumors.
We work with key collaborators, including academic institutions, pharmaceutical companies, and other key partners to advance our programs and discover new therapeutic opportunities.
While our primary focus is on the development of T-cell therapies to treat cancer, T cells also play a fundamental role in many other disease areas, most notably autoimmune disorders. We believe that our proprietary platform technologies are well-suited to better understand disease pathology and discover novel antigens for the development of targeted therapeutics for autoimmunity.
TScan is open to expanding our reach, supporting greater understanding, and driving therapeutic development in these additional disease areas through collaborations with strategic partners.
For more information, please contact us at info@tscan.com.
Current Collaboration
Amgen
In May 2023, Amgen (NASDAQ: AMGN) and TScan Therapeutics initiated a multi-year collaboration that harnesses TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights.
